| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
'Pseudopalisading' necrosis in glioblastoma: a familiar morphologic feature that links vascular pathology, hypoxia, and angiogenesis.
|
J Neuropathol Exp Neurol
|
2006
|
2.37
|
|
2
|
A vascular targeted pan phosphoinositide 3-kinase inhibitor prodrug, SF1126, with antitumor and antiangiogenic activity.
|
Cancer Res
|
2008
|
2.30
|
|
3
|
PTEN protects p53 from Mdm2 and sensitizes cancer cells to chemotherapy.
|
J Biol Chem
|
2001
|
1.66
|
|
4
|
The protein phosphatase activity of PTEN regulates SRC family kinases and controls glioma migration.
|
Cancer Res
|
2008
|
1.63
|
|
5
|
Regulation of XIAP translation and induction by MDM2 following irradiation.
|
Cancer Cell
|
2009
|
1.60
|
|
6
|
Rap1a null mice have altered myeloid cell functions suggesting distinct roles for the closely related Rap1a and 1b proteins.
|
J Immunol
|
2007
|
1.56
|
|
7
|
Mechanisms of disease: the PI3K-Akt-PTEN signaling node--an intercept point for the control of angiogenesis in brain tumors.
|
Nat Clin Pract Neurol
|
2007
|
1.44
|
|
8
|
Role of glutamine depletion in directing tissue-specific nutrient stress responses to L-asparaginase.
|
J Biol Chem
|
2006
|
1.29
|
|
9
|
PTEN and hypoxia regulate tissue factor expression and plasma coagulation by glioblastoma.
|
Cancer Res
|
2005
|
1.28
|
|
10
|
PTEN and phosphatidylinositol 3'-kinase inhibitors up-regulate p53 and block tumor-induced angiogenesis: evidence for an effect on the tumor and endothelial compartment.
|
Cancer Res
|
2003
|
1.27
|
|
11
|
Epidermal growth factor receptor and PTEN modulate tissue factor expression in glioblastoma through JunD/activator protein-1 transcriptional activity.
|
Cancer Res
|
2009
|
1.22
|
|
12
|
Early growth response gene-1 regulates hypoxia-induced expression of tissue factor in glioblastoma multiforme through hypoxia-inducible factor-1-independent mechanisms.
|
Cancer Res
|
2006
|
1.13
|
|
13
|
Molecular basis for a direct interaction between the Syk protein-tyrosine kinase and phosphoinositide 3-kinase.
|
J Biol Chem
|
2004
|
1.13
|
|
14
|
Heterozygosity for Pten promotes tumorigenesis in a mouse model of medulloblastoma.
|
PLoS One
|
2010
|
1.06
|
|
15
|
Ceramide signaling in fenretinide-induced endothelial cell apoptosis.
|
J Biol Chem
|
2002
|
1.05
|
|
16
|
SHP-1 regulates Fcgamma receptor-mediated phagocytosis and the activation of RAC.
|
Blood
|
2002
|
1.04
|
|
17
|
PHA665752, a small-molecule inhibitor of c-Met, inhibits hepatocyte growth factor-stimulated migration and proliferation of c-Met-positive neuroblastoma cells.
|
BMC Cancer
|
2009
|
1.03
|
|
18
|
Rac2 specificity in macrophage integrin signaling: potential role for Syk kinase.
|
J Biol Chem
|
2003
|
1.01
|
|
19
|
In vitro evaluation of pan-PI3-kinase inhibitor SF1126 in trastuzumab-sensitive and trastuzumab-resistant HER2-over-expressing breast cancer cells.
|
Cancer Chemother Pharmacol
|
2009
|
1.00
|
|
20
|
CSK controls retinoic acid receptor (RAR) signaling: a RAR-c-SRC signaling axis is required for neuritogenic differentiation.
|
Mol Cell Biol
|
2007
|
0.96
|
|
21
|
CSK negatively regulates nerve growth factor induced neural differentiation and augments AKT kinase activity.
|
Exp Cell Res
|
2005
|
0.88
|
|
22
|
PTEN controls immunoreceptor (immunoreceptor tyrosine-based activation motif) signaling and the activation of Rac.
|
Blood
|
2002
|
0.83
|
|
23
|
Expression of RAC2 in endothelial cells is required for the postnatal neovascular response.
|
Exp Cell Res
|
2009
|
0.83
|
|
24
|
The PI-3 kinase-Akt-MDM2-survivin signaling axis in high-risk neuroblastoma: a target for PI-3 kinase inhibitor intervention.
|
Cancer Chemother Pharmacol
|
2010
|
0.81
|
|
25
|
Pediatric phase II trials of poly-ICLC in the management of newly diagnosed and recurrent brain tumors.
|
J Pediatr Hematol Oncol
|
2014
|
0.80
|
|
26
|
Pan-PI-3 kinase inhibitor SF1126 shows antitumor and antiangiogenic activity in renal cell carcinoma.
|
Cancer Chemother Pharmacol
|
2015
|
0.80
|
|
27
|
An integrin-targeted, pan-isoform, phosphoinositide-3 kinase inhibitor, SF1126, has activity against multiple myeloma in vivo.
|
Cancer Chemother Pharmacol
|
2013
|
0.80
|
|
28
|
Synthesis and cancer stem cell-based activity of substituted 5-morpholino-7H-thieno[3,2-b]pyran-7-ones designed as next generation PI3K inhibitors.
|
J Med Chem
|
2013
|
0.79
|
|
29
|
PTEN status mediates 2ME2 anti-tumor efficacy in preclinical glioblastoma models: role of HIF1α suppression.
|
J Neurooncol
|
2013
|
0.78
|